vaccination
Washington, D.C. — Dengvaxia, the live attenuated vaccine for preventing dengue disease, was approved by the FDA late Wednesday night for children ages 9-16 with laboratory-confirmed previous dengue infection and who live in dengue-endemic areas. The vaccine protects against symptomatic disease...